Filtered By:
Drug: Diovan
Countries: Taiwan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
A Cost-Utility Analysis of Calcium Channel Blockers (Ccbs) Compared with Angiotensin II Receptor Blockers (Arbs) In Preventing Stroke And Myocardial Infarction Among Hypertension Patients In The Taiwan
Hypertension is a major risk factor for stroke and myocardial infarction (MI), which imposes a substantial burden on patients, caregivers, and society. Despite the high financial burden, limited studies have examined the cost-effectiveness of hypertension treatments in Taiwan. This cost utility analysis was conducted to determine the costs and quality-adjusted life years (QALYs) associated with amlodipine (CCB) and valsartan (ARB) in preventing stroke and MI among Taiwanese hypertension patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: C.H. Fang, K.Y. Lin, Y.C. Huang, L. Liu Source Type: research
